PMID- 34584095
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220218
IS  - 2373-8057 (Print)
IS  - 2373-8057 (Electronic)
IS  - 2373-8057 (Linking)
VI  - 7
IP  - 1
DP  - 2021 Sep 28
TI  - Eight-hours conventional versus adaptive deep brain stimulation of the 
      subthalamic nucleus in Parkinson's disease.
PG  - 88
LID - 10.1038/s41531-021-00229-z [doi]
LID - 88
AB  - This study compares the effects on motor symptoms between conventional deep brain 
      stimulation (cDBS) and closed-loop adaptive deep brain stimulation (aDBS) in 
      patients with Parkinson's Disease. The aDBS stimulation is controlled by the 
      power in the beta band (12-35 Hz) of local field potentials recorded directly by 
      subthalamic nucleus electrodes. Eight subjects were assessed in two 8-h 
      stimulation sessions (first day, cDBS; second day, aDBS) with regular levodopa 
      intake and during normal daily activities. The Unified Parkinson's Disease Rating 
      Scale (UPDRS) part III scores, the Rush scale for dyskinesias, and the total 
      electrical energy delivered to the tissues per second (TEEDs) were significantly 
      lower in the aDBS session (relative UPDRS mean, cDBS: 0.46 +/- 0.05, aDBS: 
      0.33 +/- 0.04, p = 0.015; UPDRS part III rigidity subset mean, cDBS: 
      2.9143 +/- 0.6551 and aDBS: 2.1429 +/- 0.5010, p = 0.034; UPDRS part III standard 
      deviation cDBS: 2.95, aDBS: 2.68; p = 0.047; Rush scale, cDBS 2.79 +/- 0.39 versus 
      aDBS 1.57 +/- 0.23, p = 0.037; cDBS TEEDs mean: 28.75 +/- 3.36 microj s(-1), aDBS TEEDs 
      mean: 16.47 +/- 3.33, p = 0.032 Wilcoxon's sign rank test). This work further 
      supports the safety and effectiveness of aDBS stimulation compared to cDBS in a 
      daily session, both in terms of motor performance and TEED to the patient.
CI  - (c) 2021. The Author(s).
FAU - Bocci, Tommaso
AU  - Bocci T
AD  - "Aldo Ravelli" Research Center for Neurotechnology and Experimental Brain 
      Therapeutics, Department of Health Sciences, University of Milan Medical School, 
      Milan, Italy.
AD  - III Neurology Clinic, ASST Santi Paolo e Carlo, Milan, Italy.
FAU - Prenassi, Marco
AU  - Prenassi M
AUID- ORCID: 0000-0003-0240-0860
AD  - Dipartimento in Ingegneria e Architettura, Universita degli studi di Trieste, 
      Trieste, Italy.
FAU - Arlotti, Mattia
AU  - Arlotti M
AD  - Newronika S.p.A., Milan, Italy.
FAU - Cogiamanian, Filippo Maria
AU  - Cogiamanian FM
AD  - U.O. Fisiopatologia,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milano, Italy.
FAU - Borellini, Linda
AU  - Borellini L
AD  - U.O. Fisiopatologia,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milano, Italy.
FAU - Moro, Elena
AU  - Moro E
AD  - Division of Neurology, Centre Hospitalier Universitaire de Grenoble, Grenoble, 
      France.
FAU - Lozano, Andres M
AU  - Lozano AM
AD  - Division of Neurosurgery, University of Toronto, Toronto, ON, Canada.
FAU - Volkmann, Jens
AU  - Volkmann J
AD  - Department of Neurology, University of Wurzburg, Wurzburg, Germany.
FAU - Barbieri, Sergio
AU  - Barbieri S
AD  - U.O. Fisiopatologia,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milano, Italy.
FAU - Priori, Alberto
AU  - Priori A
AUID- ORCID: 0000-0002-1549-3851
AD  - "Aldo Ravelli" Research Center for Neurotechnology and Experimental Brain 
      Therapeutics, Department of Health Sciences, University of Milan Medical School, 
      Milan, Italy. Alberto.priori@unimi.it.
AD  - III Neurology Clinic, ASST Santi Paolo e Carlo, Milan, Italy. 
      Alberto.priori@unimi.it.
FAU - Marceglia, Sara
AU  - Marceglia S
AD  - Dipartimento in Ingegneria e Architettura, Universita degli studi di Trieste, 
      Trieste, Italy.
AD  - U.O. Fisiopatologia,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
      Milano, Italy.
LA  - eng
PT  - Journal Article
DEP - 20210928
PL  - United States
TA  - NPJ Parkinsons Dis
JT  - NPJ Parkinson's disease
JID - 101675390
EIN - NPJ Parkinsons Dis. 2022 Feb 15;8(1):18. PMID: 35169155
PMC - PMC8478873
COIS- T.B, M.P., and L.B. declare no conflict of interest. A.M.L., and J.V. are 
      consultants for Medtronic, Boston Scientific, Abbott and Newronika. E.M. is a 
      consultant for Abbott, Medtronic and Newronika. F.C., S.M., S.B., and A.P. are 
      founders and shareholders of Newronika Spa. M.A. is an employer and stock options 
      holder of Newronika S.p.A.
EDAT- 2021/09/30 06:00
MHDA- 2021/09/30 06:01
PMCR- 2021/09/28
CRDT- 2021/09/29 06:09
PHST- 2020/10/28 00:00 [received]
PHST- 2021/07/23 00:00 [accepted]
PHST- 2021/09/29 06:09 [entrez]
PHST- 2021/09/30 06:00 [pubmed]
PHST- 2021/09/30 06:01 [medline]
PHST- 2021/09/28 00:00 [pmc-release]
AID - 10.1038/s41531-021-00229-z [pii]
AID - 229 [pii]
AID - 10.1038/s41531-021-00229-z [doi]
PST - epublish
SO  - NPJ Parkinsons Dis. 2021 Sep 28;7(1):88. doi: 10.1038/s41531-021-00229-z.